Literature DB >> 8423407

Control of fibrosis in systemic scleroderma.

C Mauch1, B Eckes, N Hunzelmann, T Oono, E Kozlowska, T Krieg.   

Abstract

Scleroderma is characterized by an excessive deposition of collagen in all involved organs. This is due to an overproduction of extracellular matrix (ECM) molecules following induction of gene expression, whereas there is no evidence that the composition of the connective tissue matrix is altered. Several in vivo studies and in vitro experiments suggest that a close interaction between inflammatory cells and fibroblasts is required for the initial activation of fibroblasts. TGF-beta presumably plays an important role, but other cytokines, e.g., PDGF or FGF, may also be involved. Many of the ECM molecules have been shown to interact closely with fibroblasts and provide signals that regulate fibroblast metabolism. The cellular response towards those signals is a further aspect of fibrosis that has attracted attention during recent years. The altered expression of receptor proteins on the cell surface of scleroderma fibroblasts for example might explain in part the lack of down-regulation of collagen synthesis in late phases of the disease. This review summarizes the alterations of connective tissue in scleroderma, and discusses the role of cytokines as well as the ECM for the regulation of fibroblast function and their implication for the development of fibrosis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8423407     DOI: 10.1111/1523-1747.ep12356293

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  8 in total

1.  Serum levels of soluble CD21 in patients with systemic sclerosis.

Authors:  Manabu Tomita; Takafumi Kadono; Norihito Yazawa; Tomohiko Kawashima; Zenshiro Tamaki; Ryuichi Ashida; Hanako Ohmatsu; Yoshihide Asano; Makoto Sugaya; Masahide Kubo; Hironobu Ihn; Kunihiko Tamaki; Shinichi Sato
Journal:  Rheumatol Int       Date:  2010-10-30       Impact factor: 2.631

2.  Epidermal development and wound healing in matrix metalloproteinase 13-deficient mice.

Authors:  Bettina Hartenstein; Bernd Thilo Dittrich; Dominique Stickens; Babette Heyer; Thiennu H Vu; Sibylle Teurich; Marina Schorpp-Kistner; Zena Werb; Peter Angel
Journal:  J Invest Dermatol       Date:  2006-02       Impact factor: 8.551

3.  Plasma concentration of total and transformed alpha 2-macroglobulin in systemic sclerosis.

Authors:  G Birkenmeier; R Frank
Journal:  Arch Dermatol Res       Date:  1996-06       Impact factor: 3.017

4.  Expression of a dominant-negative type II transforming growth factor beta (TGF-beta) receptor in the epidermis of transgenic mice blocks TGF-beta-mediated growth inhibition.

Authors:  X J Wang; D A Greenhalgh; J R Bickenbach; A Jiang; D S Bundman; T Krieg; R Derynck; D R Roop
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-18       Impact factor: 11.205

5.  Feline Gastrointestinal Eosinophilic Sclerosing Fibroplasia-Extracellular Matrix Proteins and TGF-β1 Immunoexpression.

Authors:  Néstor Porras; Agustín Rebollada-Merino; Fernando Rodríguez-Franco; Andrés Calvo-Ibbitson; Antonio Rodríguez-Bertos
Journal:  Vet Sci       Date:  2022-06-13

6.  Mast cells enhance contraction of three-dimensional collagen lattices by fibroblasts by cell-cell interaction: role of stem cell factor/c-kit.

Authors:  T Yamamoto; K Hartmann; B Eckes; T Krieg
Journal:  Immunology       Date:  2000-03       Impact factor: 7.397

7.  Serum levels of tissue inhibitors of metalloproteinase 2 in patients with systemic sclerosis with duration more than 2 years: correlation with cardiac and pulmonary abnormalities.

Authors:  Amira Shahin; Amani Elsawaf; Shahira Ramadan; Olfat Shaker; Mona Amin; Mohamed Taha
Journal:  Mediators Inflamm       Date:  2006       Impact factor: 4.711

8.  A targeted mutation at the known collagenase cleavage site in mouse type I collagen impairs tissue remodeling.

Authors:  X Liu; H Wu; M Byrne; J Jeffrey; S Krane; R Jaenisch
Journal:  J Cell Biol       Date:  1995-07       Impact factor: 10.539

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.